布地奈德是用来治什么的？

What is it used to treat? Budesonide is indicated for the treatment of bronchial asthma.

Budesonide is a new type of inhaled glucocorticoid asthma treatment drug, which belongs to the adrenocortical hormone drugs. Budesonide was first developed and marketed by AstraZeneca Pharmaceuticals in 1981. It is a non-halogenated glucocorticoid that has a strong local anti-inflammatory effect and can inhibit early bronchospasm and late allergic reactions. It is one of the important drugs for the treatment of allergic asthma. The safety and effectiveness of budesonide treatment were verified in the trial: 85 patients with bronchial asthma who received treatment were selected and divided into an experimental group of 43 cases and a control group of 42 cases using the random number table method. Patients in the control group were treated with albuterol sulfate, and patients in the experimental group were treated with budesonide. After 2 weeks, the treatment effects and incidence of adverse reactions were compared. Results: The treatment effectiveness rate of patients in the experimental group was 95.35%, which was significantly higher than the 69.05% in the control group, and the difference was statistically significant (P=0.05). No patients in the two groups experienced serious adverse reactions, and the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, and the difference was statistically significant (P=0.05). Conclusion Budesonide has significant efficacy and high safety when used in bronchial asthma.

It is a halogen-free topical glucocorticoid and is currently one of the most commonly used drugs for the treatment of asthma in various countries around the world. Budesonide has a strong local anti-inflammatory effect. The mechanism of action of budesonide may be: enhancing the stability of mast cells and lysosomal membranes, reducing degranulation and the release of lysosomal enzymes; anti-immune effects, inhibiting inflammation caused by immune responses, etc.; for patients with airway hyperresponsiveness, this product can significantly reduce the airway response to histamine and methacholine. About 10% of the aerosol is deposited in the lung tissue after inhalation. About 90% of the swallowed residual drugs are rapidly metabolized by the liver and inactivated.